• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-04-22

  Schwartz's dissertation challenges the traditional use of relative viability as the sole measure of anti-cancer drug efficacy in vitro, introducing a dual-metric approach that distinguishes between proliferation arrest and cell death. This innovation enables more nuanced interpretation of drug responses, supporting improved assay design and translational relevance for cancer biology research.

• Cy5 Maleimide for Site-Specific Protein Labeling Workflows

  2026-04-22

  Non-sulfonated Cy5 maleimide enables precise, high-sensitivity labeling of thiol-containing biomolecules, supporting advanced imaging and molecular partitioning studies. Its robust spectral properties and site-selectivity make it a cornerstone for protein tracking and phase separation assays in neurodegenerative research.

• Scalable Bioreactor Production of iMSC-Derived EVs for Thera

  2026-04-21

  Gong et al. present a scalable, standardized platform for producing extracellular vesicles (EVs) from induced mesenchymal stem cells (iMSCs) generated from extended pluripotent stem cells (EPSCs). By integrating suspension and fixed-bed bioreactor technologies, the study addresses key challenges in EV manufacturing and demonstrates therapeutic efficacy in a pulmonary fibrosis model, with implications for clinical translation.

• ARCA EGFP mRNA: Optimizing Fluorescence-Based Transfection A

  2026-04-21

  Leverage ARCA EGFP mRNA for rapid, quantitative assessment of mRNA transfection efficiency in mammalian cells. This guide details applied workflows, best practices, and troubleshooting strategies to maximize assay reproducibility and validate next-generation delivery systems.

• Canagliflozin: Mitochondrial Remodeling in Diabetic Kidneys

  2026-04-20

  This thought-leadership article explores the emerging role of Canagliflozin—a potent SGLT2 inhibitor—in reshaping mitochondrial structure and function within proximal tubular cells of hypertensive–diabetic mice. By integrating mechanistic insights, translational relevance, and protocol guidance, the piece empowers researchers to harness Canagliflozin's unique properties for advanced diabetes and kidney disease models. The discussion extends beyond glycemic control, highlighting the compound's implications for renal protection and energy metabolism modulation.

• BX795: Precision PDK1 Inhibition for Translational Discovery

  2026-04-20

  This thought-leadership article explores BX795, a highly selective PDK1 inhibitor, as a catalyst for translational breakthroughs in cancer and immunology. Integrating mechanistic insight, protocol guidance, and context from cutting-edge in vitro methodology, it empowers translational researchers to design robust assays and interpret complex drug responses. By linking primary literature, eScholarship, and advanced workflow recommendations, the article establishes a new standard for scientific rigor and experimental reproducibility.

• Practical Guide to YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2

  2026-04-19

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol enables direct modulation of hypoxia signaling for researchers investigating HIF-1α-associated pathways, tumor angiogenesis inhibition, and apoptosis in cancer biology. This compound is not suitable for diagnostic or therapeutic use and should be handled only in controlled research workflows.

• LY364947: Precision TGF-β Type I Receptor Kinase Inhibitor W

  2026-04-18

  LY364947 delivers highly selective, reproducible inhibition of the TGF-β type I receptor kinase, enabling robust dissection of EMT, fibrosis, and retinal degeneration processes. This guide translates recent mechanistic research into actionable experimental workflows and troubleshooting tips, empowering advanced studies in TGF-β signaling with confidence.

• Axitinib (AG 013736): Best Practices for Reliable In Vitro A

  2026-04-17

  This article provides an evidence-based, scenario-driven guide for deploying Axitinib (AG 013736) (SKU A8370) in cell viability, proliferation, and cytotoxicity assays. It addresses real-world laboratory challenges, offering quantitative context, protocol parameters, and product selection advice to help biomedical researchers achieve reproducible and robust results.

• Ferroptosis-Related Prognostic Signature and Atorvastatin in

  2026-04-16

  This study establishes a novel ferroptosis-related gene signature for prognostic prediction in hepatocellular carcinoma (HCC) and identifies Atorvastatin, an HMG-CoA reductase inhibitor, as a candidate agent capable of inducing ferroptosis in HCC cells. The findings offer a mechanistic rationale for ferroptosis-targeted strategies in HCC and provide a foundation for further translational research.

• ML-7 Hydrochloride in Cardioprotection: From Mechanism to Pr

  2026-04-15

  Explore how ML-7 hydrochloride, a potent myosin light chain kinase inhibitor, advances ischemia/reperfusion injury research by enabling precise modulation of cardiac cell death and tight junction dynamics. This article offers protocol guidance and critical insights beyond existing reviews.

• EdU Imaging Kits (HF594): Advanced Protocols & Asthma Insigh

  2026-04-14

  Explore EdU Imaging Kits (HF594) for precise 5-ethynyl-2’-deoxyuridine-based cell proliferation analysis. This in-depth article uniquely bridges technical assay optimization with new asthma research, revealing how high-fidelity DNA synthesis measurement informs immune cell studies.

• Antipyrine in High-Throughput CNS Drug Assays: Beyond Benchm

  2026-04-13

  Explore the advanced role of Antipyrine in high-throughput CNS drug screening, combining primary research with unique insights into permeability modeling. Discover why 1,5-dimethyl-2-phenylpyrazol-3-one is pivotal for translational pharmacology.

• HAUS1 in Hepatocellular Carcinoma: Prognostic Value and Immu

  2026-04-13

  This study provides a comprehensive bioinformatics and experimental analysis of HAUS1 expression in hepatocellular carcinoma (HCC), demonstrating its prognostic significance and association with the tumor immune microenvironment. Findings suggest HAUS1 as a potential biomarker and therapeutic target for HCC, advancing the mechanistic understanding of cell proliferation and immune modulation in liver cancer.

• TL1A Modulates SHP-1-Src-VE-cadherin Signaling in Diabetic R

  2026-04-12

  This study identifies tumor necrosis factor ligand-related molecule 1A (TL1A) as a critical regulator of blood-retinal barrier integrity in diabetic retinopathy. By elucidating the TL1A–SHP-1–Src–VE-cadherin signaling axis, the research provides mechanistic insights with translational relevance for vascular protection in diabetic eye disease.

15591 records 1/1040 page Next 12345 下5页 Last page